Singapore markets open in 41 minutes
  • Straits Times Index

    3,134.66
    +18.34 (+0.59%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • Dow

    35,719.43
    +492.40 (+1.40%)
     
  • Nasdaq

    15,686.92
    +461.76 (+3.03%)
     
  • BTC-USD

    50,457.92
    -6.09 (-0.01%)
     
  • CMC Crypto 200

    1,308.39
    -12.89 (-0.98%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Gold

    1,785.50
    +0.80 (+0.04%)
     
  • Crude Oil

    71.77
    -0.28 (-0.39%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • Nikkei

    28,455.60
    0.00 (0.00%)
     
  • Hang Seng

    23,983.66
    +634.28 (+2.72%)
     
  • FTSE Bursa Malaysia

    1,497.97
    +14.52 (+0.98%)
     
  • Jakarta Composite Index

    6,602.57
    +55.45 (+0.85%)
     
  • PSE Index

    7,147.30
    +16.56 (+0.23%)
     
AIRLINES:

Omicron’s rapid spread shreds budding recovery in air travel

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Spectrum and loanDepot and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and loanDepot, Inc. (NYSE: LDI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI)

Class Period: December 27, 2018 to August 5, 2021

Lead Plaintiff Deadline: November 1, 2021

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter (“CRL”) from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility will be necessary.

On this news, Spectrum's stock price fell $0.70 per share, or 21.54%, to close at $2.55 per share on August 6, 2021.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

For more information on the Spectrum class action go to: https://bespc.com/cases/SPPI

loanDepot (NYSE: LDI)

Class Period: February 11, 2021 IPO

Lead Plaintiff Deadline: November 8, 2021

In February 2021, loanDepot completed its initial public offering (“IPO”), selling 3.85 million shares of Class A common stock at $14.00 per share.

By August 17, 2021, loanDepot's stock had declined to $8.07 per share, a more than 42% decline from the IPO price after the Company disclosed disappointing second quarter 2021 financial results and provided significantly lower guidance for its business.

According to the complaint, loanDepot violated the Securities Act of 1933 because the Registration Statement failed to disclose that: (1) the Company’s loan originations had already declined substantially at the time of the IPO due to industry over-capacity and increased competition; (2) that the Company’s gain-on-sale margins had already declined substantially at the time of the IPO; (3) that, as a result, the Company’s revenue and growth would be negatively impacted; (4) that the Company had already been forced to embark on a significant expense reduction plan due to the significantly lower growth and refinance originations that the Company was experiencing; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the loanDepot class action go to: https://bespc.com/cases/LDI

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting